Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.2.4.1-1 | Award Amount: 7.74M | Year: 2011
Though survival of children with acute lymphoblastic leukaemia (ALL) has improved, relapse remains a leading cause of mortality in childhood cancer. Given the rarity of the disease, only a large international cooperative group can recruit sufficient patients for prospective studies with specific questions in biologic subgroups. Under the umbrella of the I-BFM SG all relevant mainly European study groups are creating the worldwide largest Study for Children with Relapsed ALL (IntReALL 2010). The aim is to develop optimized standard treatment as platform for systematic randomized phase II and III studies on the most promising new and targeted agents. An adequate trial structure, an optimized web based database, and standardized diagnostic methods need to be established. Patients are stratified into a standard (SR) and a high risk (HR) group according to established factors. For SR patients, the best available treatment protocols ALL-REZ BFM 2002 and ALL R3 are randomly compared, and the additional effect on survival of the humanized monoclonal CD22 directed antibody epratuzumab is investigated. HR patients who have unsatisfying remission rates will receive an intensified induction with the new nucleoside analogue clofarabine compared to standard induction therapy. IntReALL 2010 allows for comprehensive tumour banking and systematic biologic research in subgroups with correlation to clinical outcome. SMEs will be involved into project management, data base development, and pharmaceutical and biotechnological research to ensure innovation in the respective areas. IntReALL 2010 is embedded in a network of European academic structures relevant for childhood cancer. It will be a cornerstone of drug development in childhood leukaemia and the only trial with the potential for well powered phase III studies in this indication. IntReALL 2010 will harmonize ALL-relapse therapy, establish highest diagnostic and therapeutic standard and improve survival of children with ALL.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: PHC-17-2014 | Award Amount: 6.77M | Year: 2015
While Cardiovascular diseases (CVD) are the main cause of death worldwide, they are responsible for half of all deaths in Europe. The overall ageing of the European population and improving survival of patients with coronary heart disease has created a large population of older adults eligible for secondary prevention. Despite the established efficacy of cardiovascular medications, suboptimal adherence reduces their effectiveness and is the primary reason for suboptimal clinical benefit, contributing significantly to worsening of diseases and deaths at the population level. SECURE will be the first trial testing the efficacy of a fixed dose combination (FDC) polypill for secondary cardiovascular prevention in the elderly population ( 65 years old). The main objective is to evaluate the potential benefit of the FDC as a component of a cost-effective, globally available and comprehensive treatment strategy for secondary prevention of cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, stroke, and hospitalisation requiring revascularisation) as compared to standard therapy (the three components of the polypill given separately). As part of the secondary endpoints, SECURE will compare the effect of both strategies on adherence and intermediate measures of risk factor control such as lipids and blood pressure. Importantly, it will also measure the pharmacoeconomic impact of the FDC intervention as well as regional differences in all outcomes. The five-year project will thus involve subjects from seven different countries: Spain, Italy, France, Germany, Hungary, Poland and the Czech Republic. The findings and conclusions obtained in SECURE will allow the drafting of clinical guidelines and recommendations that will provide useful guidance and will serve as a reference framework for all stakeholders involved in tackling major challenges related to secondary prevention and treatment of chronic diseases in the elderly population.
Agency: Cordis | Branch: FP7 | Program: CP | Phase: ICT-2011.3.5 | Award Amount: 4.46M | Year: 2012
Skin cancer is the most commonly diagnosed type of cancer. Its early diagnosis is essential since it can be treated more effectively when detected earlier. New diagnostics aids are emerging including the recent techniques of optical coherence tomography (OCT) which permits non-invasive 3D optical biopsies of skin, improving patients quality of life. Nevertheless, the existing bulk systems are expensive (100 k), only affordable at the Hospital and thus, not sufficiently used by physicians or dermatologists as an early diagnosis tool.\nThe goal of VIAMOS is to benefit from advanced MOEMS technologies, enabling a new generation of miniature instruments. The challenge is to provide handheld, low-cost, fully parallel spectral domain miniature OCT devices (10 times cheaper, 150 times smaller), adapted for early diagnosis of cutaneous pathologies. VIAMOS will lean on the experience and results fostered from a previous European collaborative project, diffusing the technology to medical diagnostic applications. The consequence will be a significant upgrade adding new features such as heterodyne detection and integrated swept source.\nThanks to its ability to deliver high-resolution 3D topography of skin with multifunctional modules (e.g. polarization sensitive cartography), VIAMOS will propose an OCT microsystem able to revolutionize the field of microscopes for dermatology imaging.\nTo match these objectives, VIAMOS brings together an experienced consortium made of 2 academic institutions (UFC-P5 and USTUTT), 3 research institutes (VTT, FhG and CSEM) and 2 industrials (DERM and STAT), covering MEMS & MOEMS, photonics & OCT, microscopy, system integration and dermatology. A unique team of transverse expertise is gathered in VIAMOS to design and demonstrate a miniature solution for in vivo 3D skin imaging to further address the early diagnosis of cutaneous pathologies that will potentially benefit millions of people worldwide.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: PHC-15-2015 | Award Amount: 6.34M | Year: 2015
Stroke is the second leading cause of death in the world population. When not fatal, stroke often results in disability, due to motor and cognitive impairments, and secondary health problems affecting not only patients but also their families. Building on emerging preclinical and pilot clinical evidences, RESSTORE will focus on the clinical assessment of regenerative cell therapy to improve stroke recovery and patients quality of life. RESSTORE European multicentre randomised phase IIb will explore, for the first time, the efficacy (functional recovery) and safety of intravenous infusion of allogenic adipose tissue derived mesenchymal stem cells (ADMSCs) in 400 stroke patients. Therapeutic effects of ADMSCs will be assessed and monitored in patients using clinical rating scales, multimodal MRI and novel blood biomarkers. Additionally, the societal value and cost-effectiveness of ADMSCs-based regenerative therapy will be evaluated through health economics and predictive in silico simulations. Complementary ancillary animal studies will support the clinical trial by defining i) if the treatment response can be further enhanced by intensive rehabilitation, ii) the contribution of co-morbidities and iii) the mechanism(s) underlying the therapeutic effect. The European regenerative therapy capacities (France, Spain, Finland, United Kingdom and Czech Republic), developed in RESSTORE will cover the full value chain in the field (large scale GMP cell production, clinical testing, biomarkers discovery, understanding of the restoring mechanisms, modelling, biobanking, economic studies, exploitation and communication plan). RESSTORE will thus surely contribute, together with the workforce trained in the context of the programme, to improve its public and private (SME) competitiveness and increase the attractiveness of Europe as a reference location to develop and clinically assess new innovative therapeutic options for brain diseases.
French National Center for Scientific Research, ENSMM - National Engineering Institute in Mechanics, Microtechnologies and Besancon University Hospital Center | Date: 2012-01-31
The invention relates to a microrobot that is microfabricated using micro-electromechanical system technology, including i pairs of drive modules wherein i ranges from 1 to n, where n is no less than 1, the microrobot comprising: a mounting arranged so as to support at least two drive modules aligned in a first direction (x), said drive modules forming a pair of drive modules; i pairs of primary connecting-rod assemblies, each primary connecting-rod assembly being pivotably connected to the drive pin of a drive module of the i^(th )pair of drive modules; a pair of secondary connecting-rod assemblies, each secondary connecting-rod assembly being pivotably connected to the primary connecting-rod assembly of the n^(th )pair of drive modules and to the mounting; and an actuating member pivotably connected to each secondary connecting-rod assembly.
Agency: Cordis | Branch: FP7 | Program: CP | Phase: ICT-2011.2.1 | Award Amount: 3.56M | Year: 2012
Lasers form an increasingly common tool for precision treatment of pathological conditions on delicate and vital human organs. Laser phonomicrosurgery, which is a suite of complex otolaryngological surgical techniques for the treatment of minute abnormalities in the larynx, is one such example. However, laser aiming control for this procedure relies completely on the dexterity of surgeons, who must operate through a microscope and deal with its associated poor ergonomics, and this can have a strong impact on the quality of the procedures. In addition, the laser beam is directed from a comparatively large range (400mm), resulting in accuracy and consistency problems, and requiring extensive surgeon training. In this multidisciplinary project a redesign of this surgical setup is proposed to create an advanced augmented micro-surgical system through research and development of real-time cancer tissue imaging, surgeon-machine interfaces, assistive teleoperation, intelligent (cognitive) safety systems, and augmented-reality. Furthermore, research and development of new endoscopic tools and precision micro-robotic end effectors will allow relocating the laser actuator closer to the surgical site. This will allow unprecedented levels of accessibility and precision, while the surgeon will operate in a more ergonomic, information-rich, and assistive environment. The outcomes of the project will be improved quality, safety, and effectiveness in laser phonomicrosurgery, enabling total tumour removal with minimal damage to healthy tissue. The research efforts herein will generate new knowledge in the design and control of medical micro-mechatronic devices; cancer tissue imaging; assistive teleoperation in medicine; physician-robot interfaces; and cognitive computer vision. These technological advances will pave the way towards new and safer minimally invasive laser microsurgeries, leading to a significantly enhanced capacity for cancer treatment in general.
Besancon University Hospital Center and Coventya Sas | Date: 2014-03-28
The present invention relates to an electroplating bath for zinc-iron alloys as an anti-corrosive layer and to a method for depositing zinc-iron alloy on a device. The invention also relates to a device which comprises an anti-corrosive layer of a zinc-iron alloy and the use of mentioned electroplating bath.